Welcome to our dedicated page for Enveric Biosciences news (Ticker: $ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Enveric Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Enveric Biosciences's position in the market.
Rhea-AI Summary
Enveric Biosciences (ENVB) to participate in Biotech Showcase 2024, presenting business and clinical development strategy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
-
Rhea-AI Summary
Enveric Biosciences (ENVB) has identified three novel neuroplastic compounds from its EVM301 Series with the potential to offer a first-in-class approach to address difficult-to-treat disorders by promoting neuroplasticity without inducing hallucinations. The company plans to select one of the compounds for preclinical development early in 2024 in anticipation of Investigational New Drug (IND) application for a first-in-human clinical trial. Enveric’s research team successfully narrowed the EVM301 Series to three candidates with preclinical data indicating 5HT2A receptor binding, induction of neuroplasticity, and positive stress recovery outcomes in animal models showing no indication of hallucinations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
-
Rhea-AI Summary
Enveric Biosciences (ENVB) has received a Notice of Allowance from the USPTO for a patent application pertaining to its EVM301 Series of molecules, aiming to develop treatments for mental health disorders. The company is focused on developing compounds that engage neurotransmitter receptors to promote neuroplasticity, with the goal of generating therapeutic benefit without inducing hallucinations. Enveric has filed multiple composition of matter patent applications with the USPTO, and to date, has received nine Notices of Allowance for patent applications claiming compounds in the EVM201 and EVM301 Series.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.44%
Tags
Rhea-AI Summary
Enveric Biosciences (ENVB) announces the development of lead therapeutic candidate EB-373, a novel psilocin prodrug, to be published in the Journal of Medicinal Chemistry. The compound offers potential benefits for the treatment of anxiety disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
-
Rhea-AI Summary
Enveric Biosciences (ENVB) presented two posters at the Canadian Chemical Engineering Conference (CSChE 2023) showcasing the biocatalytic production of MDMA and other phenylpropylamine derivatives, as well as a synthetic biology platform for the production of novel indolethylamine derivatives as drug candidates to treat anxiety and depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
-
Rhea-AI Summary
Enveric Biosciences, Inc. (NASDAQ: ENVB) announced significant progress in the development of neuroplastogenic small-molecule therapeutics for mental health disorders. Key highlights include the completion of several initiatives to strengthen the company's IP estate, the publication of leading scientific research, and the filing of patents for novel drug candidates and compositions of matter. The company also reported favorable results from preclinical studies and showcased the leading drug discovery and research engine behind its EVM301 Series of compounds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
Rhea-AI Summary
Enveric Biosciences has received a Notice of Allowance from the US Patent and Trademark Office for a patent application involving their lead clinical candidate, EB-373. The patent includes composition of matter claims for a family of novel prodrug derivatives of psilocin. Enveric has filed multiple composition of matter patent applications for psilocin prodrugs and has obtained seven NoAs so far. The company aims to establish a robust intellectual property position to develop improved treatments for mental health disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
-
Rhea-AI Summary
Enveric Biosciences CEO to present at Centurion One 5th Global Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
-
Rhea-AI Summary
Enveric Biosciences initiates GLP-toxicology and safety pharmacology studies for lead prodrug candidate EB-373
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
Rhea-AI Summary
Enveric Biosciences presents research on neuroplastogenic therapeutics at Neuropsychiatric Drug Development Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.04%
Tags
Enveric Biosciences, Inc.
Nasdaq:ENVB
ENVB Rankings
ENVB Stock Data
6.71M
7.17M
7.06%
6.71%
3.49%
Semiconductor and Related Device Manufacturing
Manufacturing
United States of America
NAPLES
About ENVB
ameri100 embodies a value system of ambition, mastery, excitement, reliability and integrity. with these values, the company is becoming an emerging global leader in sap technologies. ameri100, founded in 2013 has rapidly grown through strategic acquisitions. headquartered in princeton, new jersey, with offices in new york, georgia, kansas, pennsylvania, arizona, toronto- canada and bangalore, mumbai, chennai in india, ameri100 brings 500+ of its own best-in-class resources. the company has also evolved a unique partner ecosystem, which adds more than 4500+ resources to its delivery muscle power. ameri100 deals with sap enterprise services, digital transformation, cloud solutions, business intelligence & analytics, mobile applications and professional services. the company is also making strategic investments in artificial intelligence (ai), internet of things (iot) and robotic process automation (rpa). insight to impact!